During the last session, PTC Therapeutics Inc (NASDAQ:PTCT)’s traded shares were 0.79 million, with the beta value of the company hitting 0.51. At the end of the trading day, the stock’s price was $48.52, reflecting an intraday loss of -0.76% or -$0.37. The 52-week high for the PTCT share is $58.38, that puts it down -20.32 from that peak though still a striking 40.81% gain since the share price plummeted to a 52-week low of $28.72. The company’s market capitalization is $3.85B, and the average trade volume was 1.22 million shares over the past three months.
PTC Therapeutics Inc (PTCT) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.94. PTCT has a Sell rating from 2 analyst(s) out of 7 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.17.
PTC Therapeutics Inc (NASDAQ:PTCT) trade information
PTC Therapeutics Inc (PTCT) registered a -0.76% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.76% in intraday trading to $48.52, hitting a weekly high. The stock’s 5-day price performance is 6.59%, and it has moved by -2.65% in 30 days. Based on these gigs, the overall price performance for the year is 33.04%.
The consensus price target of analysts on Wall Street is $62, which implies an increase of 21.74% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $58 and $66 respectively. As a result, PTCT is trading at a discount of -36.03% off the target high and -19.54% off the low.
PTC Therapeutics Inc (PTCT) estimates and forecasts
In the rating firms’ projections, revenue will increase 85.47% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 172.85M as predicted by 11 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to 196.47M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 186.7M and 196.79M respectively. In this case, analysts expect current quarter sales to shrink by -7.42% and then drop by -0.16% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.04%. While earnings are projected to return 263.45% in 2025, the next five years will return 55.77% per annum.
PTCT Dividends
PTC Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 8.21 million shares, is of WELLINGTON MANAGEMENT GROUP LLP’s that is approximately 10.6987% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $251.02 million.
Also, the Mutual Funds coming in first place with the largest holdings of PTC Therapeutics Inc (PTCT) shares are VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Jan 31, 2025 indicates that VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund owns about 2.8 shares. This amounts to just over 3.53 percent of the company’s overall shares, with a $135.69 million market value. The same data shows that the other fund manager holds slightly less at 2.42, or about 3.05% of the stock, which is worth about $117.47 million.
